Low-Level Viremia in HIV/AIDS Patients Posing Challenges Globally

Strategic Insights -

A new study highlights the challenges posed by low-level viremia in HIV/AIDS patients, even when they are receiving effective antiretroviral therapy. The study, conducted in Chongqing, China, shows that despite the use of effective antiretroviral therapy, low-level viremia remains a significant issue, with reported prevalence rates ranging from 10-46% in resource-limited settings. The study's findings underscore the need for clearer risk stratification in diverse clinical settings, as the clinical significance of low-level viremia remains controversial.

Key Takeaways:

  • Low-level viremia during effective antiretroviral therapy presents ongoing management challenges globally, with reported prevalence rates of 10-46% in resource-limited settings.
  • The clinical significance of low-level viremia remains controversial, with some studies demonstrating that viral load levels exceeding 200 copies/mL predict virologic failure, while others report no significant association.
  • Protective factors against virologic failure include baseline viral load and viral load levels during low-level viremia, emphasizing the need for vigilant viral load monitoring and adherence support.
  • A retrospective cohort study of 1,214 individuals with low-level viremia found that 2.64% developed virologic failure, and 28.09% developed persistent low-level viremia.
  • The study highlights the need for clearer risk stratification in diverse clinical settings, as the clinical significance of low-level viremia remains controversial.

Statistics:

  • 10-46% prevalence rate of low-level viremia in resource-limited settings (a)
  • 2.64% of participants developed virologic failure (b)
  • 28.09% of participants developed persistent low-level viremia (b)
  • 1,214 participants in the study (c)
  • 2019-2023 study period (d)

Sources:

  • (a) NewsRx. Researchers at Sixth People's Hospital Have Reported New Data on HIV/AIDS (Risk factors for virologic failure and persistent low-level viremia in people with HIV experiencing low-level viremia: Chongqing ART cohort study, 2019-2023). AIDS Weekly. October 20, 2025; p 188.
  • (b) Risk factors for virologic failure and persistent low-level viremia in people with HIV experiencing low-level viremia: Chongqing ART cohort study, 2019-2023. Frontiers in Medicine, 2025;12:1660030.
  • (c) Jinjin Liu, Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, Sixth People's Hospital of Zhengzhou), Zhengzhou, People's Republic of China.
  • (d) Frontiers in Medicine. Publisher contact information for the journal is: Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland.